News

Due to negative results, the I-SPY COVID Trial is no longer evaluating cyproheptadine to treat critically ill COVID-19 patients.

In the latest SIDP column, two clinicians provide information on recent studies and guidelines directed at antibiotic durations in this patient population.

Health programs and efforts to inform the public about the importance of sharing liver education can play a major role in prevention as well as patient care.

During the COVID-19 pandemic, cigarette sales differed from projected sales volume. One study examined these trends at the state level.

Sexually transmitted infections (STIs) received little attention during the pandemic, but the truth is the STIs did not stop infection increases shortly after the quarantine.

Although medical masks were noninferior to N95 in a multinational study of frontline health care workers, variability in circumstances between countries prevented researchers from drawing firm conclusions.

This unusual Case Study describes a young woman who presented with an acute onset of headaches and dizziness and was found to have aseptic meningitis.

A look back on some of the significant discussions with clinicians, researchers, and infectious disease stakeholders.

For providers on the front lines, lessons learned can help inform strategies to enhance the protection of their health going forward.

Changes in microbiology and antimicrobial resistance patterns warrant reevaluation of our current therapies for this condition.

Clinicians can make room for infrequent treatment options as patients enjoy their daily lives.

New booster shots, antigen testing, and a shrinking incubation period: these were the top COVID-19 stories of 2022.

Vaccinations and mitigations for COVID-19 and other respiratory viruses have not been made a priority for young children. Let’s change this before the next big surge hits.

Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.

A new monoclonal antibody, invasive group A strep, and genital herpes topped the list of this week's most-read stories.

The new recommendation from the organization believes it will help avoid delays in patient care.

This study was one of the largest to address the use of IV ceftriaxone in the context of MSSA bacteremia compared with cefazolin.

Virax Biolabs has developed a T-cell testing platform to develop an immune risk profile against viral threats.

This therapy is the first of a new class of antiretrovirals, and it is indicated for people with multi-drug resistance, intolerance, or safety considerations.

Telemedicine use is likely to continue expanding even as the COVID-19 pandemic slowly resolves.

Roche’s Actemra is the first FDA approved monoclonal antibody to be used for COVID-19.

The committee will meet on January 26 to discuss whether and how the composition for primary doses of the currently available COVID-19 vaccines should be modified.

Editor-in-Chief Jason Gallagher discusses the surging number of cases of influenza and RSV while there is a concomitant shortage of amoxicillin suspension.

A central portal to support clinical practice for patients with or at risk for HIV was launched.

In this mini-podcast, infectious diseases clinical pharmacy specialist Bruce M. Jones, PharmD, FIDSA, BCPS, breaks down the “very straightforward criteria” he uses to decide whether a skin and soft tissue infection (SSTI) patient should be inpatient or outpatient.

This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.

Genital herpes (HSV-2) affects quality-of-life but also causes substantial economic losses, especially in low- and middle-income countries.

The New Drug Application (NDA) for the company’s investigational therapy, Olorofim, looks to serve an unmet medical need in this treatment space.

The Centers for Disease Control and Prevention (CDC) is looking into the possibility of this rare group of infections emerging.

2 years after the COVID-19 vaccine, we're focusing on who is still getting the most severe disease and why.